Imugene Ltd: Proposed issue of securities - IMU
Imugene Ltd: Notice of Extraordinary General Meeting/Proxy Form
Imugene Ltd: Issuance of Convertible Notes & Warrants for up to $46m
Imugene Ltd: Azer-cel Accepted for Presentation at ASTCT Tandem Meetings
Imugene Ltd: Imugene Confirms Pending Receipt of c.$11m R&D Tax Refund
Imugene Ltd: Updated Appendix 3Z
Imugene Ltd: Final Director's Interest Notice
Imugene Ltd: Director Resignation
Imugene Ltd: Imugene 2024 AGM Results
Imugene Ltd: Imugene AGM Presentation
Imugene Ltd: onCARlytics Trial Doses First Patient in IT Combination Arm
Imugene Ltd: Imugene Opens First Australian Site for azer-cel Trial
Imugene Ltd: Complete Response in MAST Study Maintained Over Two Years
Imugene Ltd: Quarterly Activities/Appendix 4C Cash Flow Report
Imugene Ltd: Notification regarding unquoted securities - IMU
Imugene Ltd: Notification of cessation of securities - IMU
Imugene Ltd: Application for quotation of securities - IMU
Imugene Ltd: Notice of Annual General Meeting/Proxy Form
Imugene Ltd: Change of Director's Interest Notice - PH
Imugene Ltd: Imugene Receives Orphan Drug Designation for VAXINIA